Cytonet's Liver Cell Therapy May Be Effective In Stabilizing Patients With Urea Cycle Disorders Awaiting Liver Transplant

Published: Jun 03, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OTTAWA, Ontario & RALEIGH-DURHAM, N.C.--(BUSINESS WIRE)--New data on Cytonet’s investigational liver cell therapy (LCT) found it may help temporarily stabilize pediatric patients with Urea Cycle Disorders (UCD) while they await liver transplantation. The study was presented at the 2014 Joint Garrod and Canadian Newborn and Child Screening Symposium in Ottawa, Ontario on May 31, 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news